US5288711A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating hyperproliferative vascular disease
Assignee: Wyeth LLC
•
Filing: 1992-04-28
•
Granted: 1994-02-22
•
Expires: 2012-04-28
Abstract
Abstract This invention provides a method of preventing or treating hyperproliferative vascular disease in a mammal by administering an antiproliferative effective amount of a combination of rapamycin and heparin.
Inventors
- 👤 Robert D. Mitchell
- 👤 Stephen Skwish
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
64 words
A method of treating vascular disease resulting from smooth muscle cell proliferation in a mammal in need thereof which comprises, administering an antiproliferative effective amount of the combination of rapamycin in a concentration of at least 1 nM and heparin in a concentration of at least 1 μg/ml to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via an impregnated vascular stent.
Claim 2
Independent Claim
64 words
A method of treating vascular disease resulting from smooth muscle cell proliferation in a mammal in need thereof which comprises, administering an antiproliferative effective amount of the combination of rapamycin in a concentration of at least 1 nM and heparin in a concentration of at least 1 μg/ml to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via an impregnated vascular stent.
Claim 3
Dependent Claim
24 words
The method according to claim 1 wherein the vascular disease resulting from smooth muscle cell proliferation is intimal smooth muscle cell hyperlasia or restenosis.
Claim 4
Dependent Claim
26 words
The method according to claim 2 wherein the combination of rapamycin and heparin is administered concurrent with said mammal undergoing a percutaneous transluminal coronary angioplasty procedure.
Claim 5
Dependent Claim
13 words
The method according to claim 3 wherein the hyperproliferative vascular disease is restenosis.
Claim 6
Dependent Claim
26 words
The method according to claim 2 wherein the combination of rapamycin and heparin is administered subsequent to said mammal undergoing a percutaneous transluminal coronary angioplasty procedure.
Claim 7
Dependent Claim
13 words
The method according to claim 5 wherein the hyperproliferative vascular disease is restenosis.
Claim 8
Dependent Claim
27 words
The method according to claim 2 wherein the combination of rapamycin and heparin is administered concurrent with said mammal sustaining a biologically or mechanically mediated vascular injury.
Claim 9
Dependent Claim
27 words
The method according to claim 2 wherein the combination of rapamycin and heparin is administered subsequent to said mammal sustaining a biologically or mechanically mediated vascular injury.
Claim 10
Dependent Claim
49 words
A composition for the use in preventing or treating hyperproliferative vascular disease in a mammal which comprises an antiproliferative effective amount of a combination of rapamycin in a concentration of at least 1 nM and heparin in a concentration of at least 1 μg/ml and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
49 words
A composition for the use in preventing or treating hyperproliferative vascular disease in a mammal which comprises an antiproliferative effective amount of a combination of rapamycin in a concentration of at least 1 nM and heparin in a concentration of at least 1 μg/ml and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
24 words
The composition according to claim 9 wherein the vascular disease resulting from smooth muscle cell proliferation is intimal smooth muscle cell hyperplasia or restenosis.
Claim 13
Dependent Claim
19 words
The method according to claim 1 wherein the vascular disease resulting from smooth muscle cell proliferation is vascular occlusion.
Claim 14
Dependent Claim
19 words
The composition according to claim 9 wherein the vascular disease resulting from smooth muscle cell proliferation is vascular occlusion.
Claim 15
Independent Claim
49 words
A method of treating restenosis in a mammal resulting from said mammal undergoing a percutaneous transluminal coronary angioplasty procedure which comprises administering an antirestenosis effective amount of a combination of rapamycin and heparin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via an impregnated vascular stent.
Claim 16
Independent Claim
49 words
A method of treating restenosis in a mammal resulting from said mammal undergoing a percutaneous transluminal coronary angioplasty procedure which comprises administering an antirestenosis effective amount of a combination of rapamycin and heparin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via an impregnated vascular stent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-02-21 | 1997-08-23 | 1998-02-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-02-21 | 2001-08-23 | 2002-02-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-02-21 | 2005-08-23 | 2006-02-22 | $7700.00 | Window Closed / Lapsed |